Skip directly to content

Coronavirus (COVID-19) Updates


Pfizer Inc. and BioNTech annouce Phase 3 study results for COVID-19 vaccine candidate.


In confronting this crisis, we believe that science will win.


This is a first but critical step in our work to deliver an effective vaccine.


Ben Osborn discusses the final stages of the global clinical trials for our candidate vaccine with partner BioNTech.
 


There are three key areas where, as with all vaccines, we must demonstrate success in order to seek approval for public use.


Nine CEOs sign pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of COVID-19 vaccines.


In the global battle against COVID-19, we're focusing on a technology called an mRNA vaccine. Learn more about the science behind mRNA vaccines.


We're working determinedly in collaboration with BioNTech to bring forward a vaccine. Learn more about mRNA vaccines.


Pfizer CEO Albert Bourla talks to Forbes about our unprecedented efforts in response to COVID-19.


Our UK Oncology Director, Dr Olivia Ashman, joins Clare English on the 17th May 'Ripples' podcast.


First U.S. participants have been dosed in the clinical trial for the global vaccine programme.


Emma Lynn, Pfizer UK Director of Corporate Affairs, explains how Pfizer is helping to bring science into the homes of children across the UK amid COVID-19.


Ben Osborn, Pfizer UK Managing Director, discusses the essential role that Pfizer colleagues have played and continue to play during the COVID crisis.


Pfizer UK R&D leaders discuss the latest scientific developments and the essential role of partnerships during the COVID-19 crisis.


Listen back to the 10th April radio broadcast on BBC Sounds using the link above.


Pfizer Inc. announces important advances in the battle against the global COVID-19 pandemic.


The donation addresses the urgent needs of partners who are working to slow the spread of the virus and strengthen vulnerable healthcare systems.


The collaboration aims to accelerate development of BioNTech’s potential COVID-19 mRNA vaccine programme.


Chairman and CEO Albert Bourla calls on biopharma industry to collaborate on combatting the global pandemic.

 

PP-PFE-GBR-3221 / Nov 2020